STAGE III LUNG CANCER AJCC V8
Clinical trials for STAGE III LUNG CANCER AJCC V8 explained in plain language.
Never miss a new study
Get alerted when new STAGE III LUNG CANCER AJCC V8 trials appear
Sign up with your email to follow new studies for STAGE III LUNG CANCER AJCC V8, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Experimental combo aims to reignite immune attack on lung cancer
Disease control Not yet recruitingThis phase 2 trial tests whether combining SX-682 (a drug that blocks certain immune-suppressing proteins) with atezolizumab (an immunotherapy) can shrink tumors in people with advanced non-small cell lung cancer that has worsened after chemotherapy and immunotherapy. About 32 ad…
Matched conditions: STAGE III LUNG CANCER AJCC V8
Phase: PHASE2 • Sponsor: University of Washington • Aim: Disease control
Last updated Jun 27, 2026 13:05 UTC
-
Can a smaller dose of this cancer drug still work? new trial aims to find out
Disease control Not yet recruitingThis phase 2 trial is testing whether a lower dose of the immunotherapy drug nivolumab, given less often, can still control cancer in people with various advanced or metastatic cancers. The goal is to see if a cheaper, more accessible regimen works as well as the standard high-co…
Matched conditions: STAGE III LUNG CANCER AJCC V8
Phase: PHASE2 • Sponsor: Fred Hutchinson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 12:30 UTC
-
New combo therapy targets hard-to-treat lung cancer mutation
Disease control Not yet recruitingThis study tests whether adding a cancer vaccine (CIMAVAX-EGF) to standard targeted drugs (sotorasib or adagrasib) can help control advanced lung cancer with a KRAS G12C mutation. About 29 adults with stage III or IV non-small cell lung cancer will receive the combination. The go…
Matched conditions: STAGE III LUNG CANCER AJCC V8
Phase: PHASE2 • Sponsor: Roswell Park Cancer Institute • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
Spinal tap could predict lung cancer spread to brain
Knowledge-focused Not yet recruitingThis pilot study will check if tumor DNA in spinal fluid can predict brain metastases in 40 patients with stage III or IV non-small cell lung cancer. Participants will undergo a lumbar puncture to collect cerebrospinal fluid, plus blood draws and an MRI six months later. The goal…
Matched conditions: STAGE III LUNG CANCER AJCC V8
Phase: NA • Sponsor: Ohio State University Comprehensive Cancer Center • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:05 UTC